Tackling Rare and Orphan Diseases by Henry I. Miller

The Case for #RareDisease Research  #SNRTG #BigData #genomics #biotech #science @henryimiller

  • Medical professionals often know little about the symptoms and biology of these diseases.
  • Policymakers can create financial incentives – which could include tax breaks on research and development – to encourage drug companies to develop therapies that otherwise would not provide an attractive return on investment.
  • The economic block on drug development is not just limited to rare diseases.
  • In the United States, rare diseases are defined as those that affect fewer than 200,000 people.
  • STANFORD – Rare diseases are commonly neglected, simply because they are, well, rare.

Read the full article, click here.


@Primary_Immune1: “The Case for #RareDisease Research #SNRTG #BigData #genomics #biotech #science @henryimiller”


In the US, rare diseases are defined as those that affect fewer than 200,000 people. But there are more than 6,800 of these conditions, and worldwide they afflict hundreds of millions of people, and only about 250 treatments are available.


Tackling Rare and Orphan Diseases by Henry I. Miller

You might also like More from author

Comments are closed, but trackbacks and pingbacks are open.